Leuven, Belgium – December 4th, 2024 – miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.
Ghent, Belgium, 4 December 2024 – European health technology (HealthTech) is at a critical crossroad. Despite groundbreaking research, a thriving startup scene and ambitious talent, the sector struggles to translate innovation into actionable impact. Challenges such as regulatory restrictions, fragmented markets, and funding gaps are slowing progress, while the clock is ticking and other regions of the world are surging ahead.
Ghent, Belgium, 4 December 2024 - At MEDVIA, we see the future of HealthTech filled with potential – a future powered by the intersection of health and technology. This is where breakthroughs in healthtech, medtech, AI and digital solutions promise to transform care delivery. It’s where patients have a voice, hospitals and caregivers have access to cutting-edge innovations, and technology like AI is making personalized medicine a reality. That future isn’t distant; it’s already here.
Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. ● New financing will accelerate preclinical development of Refoxy’s lead program in IPF as well as the expansion of its platform to additional age-related indications.
A world where we can 3D bioprint organs on demand is creeping ever closer to clinical reality, thanks to Belgian efforts to standardize the biomaterials necessary. Achieving this will have profound consequences for organ transplants, disease modeling, tissue engineering, personalized medicine, and drug discovery. But bioprinting success depends on multidisciplinary collaborations between material scientists, hardware manufacturers, clinicians, and other partners. Recently, these collaborations have reached the stratosphere, with a project to study cardiovascular aging with a heart-on-a-chip… in space!
Cervical cancer is largely curable if detected early enough and yet it remains a leading cause of death in women globally. Why? Although researchers recently made the biggest improvement in cervical cancer treatment in more than 20 years, cutting the risk of death by over 40%, effective and inclusive screening remains crucial for early detection and treatment. However, recent research from Belgium suggests that certain populations of vulnerable women or those with a migration background are falling through the cervical cancer screening cracks.
Precision oncology, which tailors cancer treatments to an individual’s specific biological characteristics, has advanced significantly in recent years. Doctors are now using more targeted therapies that focus on specific cues or biomarkers in tissues, making treatments more personalized. Nevertheless, cancer is still a tough disease to fight, and many treatments do not consistently eliminate tumors. This is where the power of multiplex imaging comes in.
Would you like the opportunity to explore your genetic predispositions? Genetic testing can be empowering, helping you to make informed decisions about your healthcare. But using DNA analysis to diagnose and predict certain health conditions calls for trained genetic professionals to explain complex results, answer lingering questions and provide emotional support to people, especially when they’re receiving unexpected news. Genetic counselors are an important link in this chain, but their crucial healthcare role is yet to be recognized in Belgium.
Leuven, Belgium – December 4th, 2024 – miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.
Ghent, Belgium, 4 December 2024 – European health technology (HealthTech) is at a critical crossroad. Despite groundbreaking research, a thriving startup scene and ambitious talent, the sector struggles to translate innovation into actionable impact. Challenges such as regulatory restrictions, fragmented markets, and funding gaps are slowing progress, while the clock is ticking and other regions of the world are surging ahead.
Ghent, Belgium, 4 December 2024 - At MEDVIA, we see the future of HealthTech filled with potential – a future powered by the intersection of health and technology. This is where breakthroughs in healthtech, medtech, AI and digital solutions promise to transform care delivery. It’s where patients have a voice, hospitals and caregivers have access to cutting-edge innovations, and technology like AI is making personalized medicine a reality. That future isn’t distant; it’s already here.
Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. ● New financing will accelerate preclinical development of Refoxy’s lead program in IPF as well as the expansion of its platform to additional age-related indications.
A world where we can 3D bioprint organs on demand is creeping ever closer to clinical reality, thanks to Belgian efforts to standardize the biomaterials necessary. Achieving this will have profound consequences for organ transplants, disease modeling, tissue engineering, personalized medicine, and drug discovery. But bioprinting success depends on multidisciplinary collaborations between material scientists, hardware manufacturers, clinicians, and other partners. Recently, these collaborations have reached the stratosphere, with a project to study cardiovascular aging with a heart-on-a-chip… in space!
Cervical cancer is largely curable if detected early enough and yet it remains a leading cause of death in women globally. Why? Although researchers recently made the biggest improvement in cervical cancer treatment in more than 20 years, cutting the risk of death by over 40%, effective and inclusive screening remains crucial for early detection and treatment. However, recent research from Belgium suggests that certain populations of vulnerable women or those with a migration background are falling through the cervical cancer screening cracks.
Precision oncology, which tailors cancer treatments to an individual’s specific biological characteristics, has advanced significantly in recent years. Doctors are now using more targeted therapies that focus on specific cues or biomarkers in tissues, making treatments more personalized. Nevertheless, cancer is still a tough disease to fight, and many treatments do not consistently eliminate tumors. This is where the power of multiplex imaging comes in.
Would you like the opportunity to explore your genetic predispositions? Genetic testing can be empowering, helping you to make informed decisions about your healthcare. But using DNA analysis to diagnose and predict certain health conditions calls for trained genetic professionals to explain complex results, answer lingering questions and provide emotional support to people, especially when they’re receiving unexpected news. Genetic counselors are an important link in this chain, but their crucial healthcare role is yet to be recognized in Belgium.